Literature DB >> 10551322

Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line.

T Harayama1, E Ohuchi, T Aoki, H Sato, M Seiki, Y Okada.   

Abstract

Membrane type 1 matrix metalloproteinase (MT1-MMP) with a transmembrane domain is a new member of the MMP gene family and is expressed on the cell surfaces of many carcinoma cells to activate the zymogen of MMP-2 (gelatinase A). We have previously reported that MT1-MMP is released into culture media in a complex form with tissue inhibitor of metalloproteinases 2 (TIMP-2) from a human breast carcinoma cell line, MDA-MB-231, treated with concanavalin A (Con A). In the present study, we further studied the release mechanism of MT1-MMP. Immunoblot analysis indicated that the amounts of MT1-MMP in culture media increase with the time of exposure and the concentration of Con A, and those in cell lysates conversely decrease in a similar way. Time- and dose-dependent release of MT1-MMP into the media was confirmed by a sandwich enzyme immunoassay specific to MT1-MMP. The molecular weight of the immunoreactive MTI-MMP in the media was Mr 56,000, which was 4,000-Mr smaller than that in the cell lysates. Northern blot analysis demonstrated that the mRNA expression level of MT1-MMP is about 3-fold enhanced after a 24 h-exposure to Con A and this is maintained up to 72-h exposure. The release of MT1-MMP from the Con A-treated cells was inhibited by metalloproteinase inhibitors such as EDTA and o-phenanthroline, but not by MMP inhibitors including TIMP-1, TIMP-2 and BB94 or other proteinase inhibitors of serine, cysteine and aspartic proteinases. During the Con A treatment of the cells, cell viability decreased time- and dose-dependently and dead cells reacted positively in the TdT-mediated dUTP Nick-End Labeling (TUNEL) method. Con A-treated MDA cells showed apoptotic morphology when stained with Hoechst dye and hematoxylin and eosin. DNA ladder formation was detected by electrophoresis of the DNA from Con A-treated MDA cells. These results suggest that MT1-MMP release from Con A-treated cells is due to shedding mediated by metalloproteinase(s) other than MMPs, and is associated with apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551322      PMCID: PMC5926159          DOI: 10.1111/j.1349-7006.1999.tb00839.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  42 in total

Review 1.  Programmed cell death, apoptosis and killer genes.

Authors:  L M Schwartz; B A Osborne
Journal:  Immunol Today       Date:  1993-12

Review 2.  Activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase
Journal:  Biol Chem       Date:  1997 Mar-Apr       Impact factor: 3.915

3.  Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.

Authors:  A Pandiella; J Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

4.  Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.

Authors:  H Ueno; H Nakamura; M Inoue; K Imai; M Noguchi; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

5.  Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2.

Authors:  K Imai; E Ohuchi; T Aoki; H Nomura; Y Fujii; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

6.  Cleavage processing of angiotensin-converting enzyme by a membrane-associated metalloprotease.

Authors:  R Ramchandran; I Sen
Journal:  Biochemistry       Date:  1995-10-03       Impact factor: 3.162

7.  Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors.

Authors:  J Arribas; L Coodly; P Vollmer; T K Kishimoto; S Rose-John; J Massagué
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

8.  Regulation of programmed death in erythroid progenitor cells by erythropoietin: effects of calcium and of protein and RNA syntheses.

Authors:  L L Kelley; M J Koury; M C Bondurant
Journal:  J Cell Physiol       Date:  1992-06       Impact factor: 6.384

9.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.

Authors:  H Nakamura; H Ueno; K Yamashita; T Shimada; E Yamamoto; M Noguchi; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

10.  Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.

Authors:  A Kvanta; E Kontny; M Jondal; S Okret; B B Fredholm
Journal:  Cell Signal       Date:  1992-05       Impact factor: 4.315

View more
  7 in total

1.  Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells.

Authors:  B Annabi; A Pilorget; N Bousquet-Gagnon; D Gingras; R Béliveau
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

Review 2.  The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis.

Authors:  T E VanMeter; H K Rooprai; M M Kibble; H L Fillmore; W C Broaddus; G J Pilkington
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

3.  Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase.

Authors:  Marta Toth; Pamela Osenkowski; Dusan Hesek; Stephen Brown; Samy Meroueh; Wael Sakr; Shahriar Mobashery; Rafael Fridman
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

4.  Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas.

Authors:  Timothy E Van Meter; William C Broaddus; Harcharan K Rooprai; Geoffrey J Pilkington; Helen L Fillmore
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

Review 5.  Significance of matrix metalloproteinases in the pathophysiology of the ovary and uterus.

Authors:  Toshiaki Endo; Tamotsu Kiya; Taeko Goto; Hirofumi Henmi; Kengo Manase; Hiroyuki Honnma; Tsuyoshi Baba; Shinichi Ishioka; Takuhiro Hayashi; Manabu Chida; Kazuyo Arima; Kiyohiro Yamazaki; Mika Kanaya; Atsushi Azumaguchi; Osamu Moriwaka; Hirofumi Kamiya; Tsuyoshi Saito
Journal:  Reprod Med Biol       Date:  2006-11-23

Review 6.  Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.

Authors:  Xiaonan Zhang; Stig Linder; Martina Bazzaro
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

7.  The Catalytic Domain Mediates Homomultimerization of MT1-MMP and the Prodomain Interferes with MT1-MMP Oligomeric Complex Assembly.

Authors:  Marton Fogarasi; Simona Dima
Journal:  Biomolecules       Date:  2022-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.